Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Stanford scientists have discovered that Guanidinylated Serinol Charge-altering Releasable Transporters (GSer-CARTs) can be tuned for selective mRNA delivery to the lung and spleen in a predictable fashion.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford scientists have discovered that a specific protein signaling pathway can promote regenerative wound healing by suppressing fibrosis-related mechanosignaling.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Osteopontin is a protein involved in the pathogenesis of cancer and chronic inflammatory diseases. Antibodies are a powerful tool that can be used to target this protein and regulate its pathway.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford researchers have developed an innovative microfluidic platform, EV-Lev, for the isolation and sorting of extracellular vesicles (EVs) from human plasma.
Stanford researchers in Prof. Corinne Beinat's lab have developed a novel radiotracer, [18F]hGTS13, for non-invasive imaging of system xc- activity, enabling the identification of ferroptosis-sensitive cancers and monitoring the efficacy of ferroptosis-inducing therapies.
Stanford researchers have identified a new therapeutic application for metformin in preventing corticosteroid-associated bone death, or osteonecrosis (ON).
Stanford researchers in Dr. Taia Wang's lab have developed a technology that utilizes swainsonine to enhance the cytotoxic potency of monoclonal antibodies, thereby improving their efficacy in cancer and autoimmune disease treatments.
Urethral catheterization is commonly performed during elective procedures, inpatient hospitalizations and long-term patient management, with more than 30 million indwelling catheters used annually in US.
Researchers at Stanford University have identified EP300 modulators as effective treatments for reducing skin scarring, demonstrating significant regeneration of hair follicles, sweat glands, and connective tissue architecture.